Should I do chemotherapy before or after surgery for HER2-Low Breast Cancer

Chemotherapy Timing for HER2-Low Breast Cancer

I appreciate this important question about treatment sequencing. Let me help you understand the clinical thinking around this decision, though I want to be clear that your specific situation requires your oncologist's evaluation based on your complete medical picture.

Understanding HER2-Low Breast Cancer

First, it's helpful to know that HER2-low breast cancer is a relatively newer classification. According to the sources available to me, HER2 protein levels are important biomarkers—when measured via proteomics, HER2 levels above 750 amol per microgram indicate HER2 overexpression, which typically opens up specific treatment pathways like dual anti-HER2 therapies (pertuzumab and trastuzumab).

HER2-low status (meaning lower but detectable HER2 expression) represents a distinct group that may benefit from newer antibody-drug conjugates like trastuzumab deruxtecan (Enhertu).

How Doctors Think About Timing

Oncologists typically consider several factors when deciding between neoadjuvant chemotherapy (before surgery) versus adjuvant chemotherapy (after surgery):

Neoadjuvant approach (chemo first):

• Allows doctors to see how your tumor responds to treatment before surgery
• May shrink the tumor, potentially allowing less extensive surgery
• Provides real-time information about treatment effectiveness

Adjuvant approach (surgery first):

• Removes the tumor immediately
• Allows pathologists to fully analyze the tumor tissue after removal
• Provides complete staging information to guide subsequent treatment

Important Questions to Ask Your Oncologist

Since treatment sequencing is highly individualized, I'd recommend asking your care team:

1. What is the stage of my cancer, and does that influence the timing recommendation? (Early-stage cancers may be approached differently than advanced disease)

2. What is my specific HER2 status, and how does that affect which drugs you're recommending? (This helps you understand if newer agents like Enhertu are being considered)

3. Would neoadjuvant chemotherapy help shrink my tumor before surgery, or do you recommend surgery first? (This gets at the clinical reasoning for your specific case)

4. What additional biomarker testing would you recommend? (Hormone receptor status, genomic testing, etc., all influence the overall treatment plan)

5. How will you monitor my response to treatment, and what would change your approach if the tumor doesn't respond as expected?

Key Consideration: Personalized Medicine

The sources emphasize that modern cancer care increasingly relies on personalized treatment recommendations based on your tumor's specific characteristics. For HER2-low breast cancer specifically, newer testing approaches can help identify which targeted therapies (like antibody-drug conjugates) might be most effective for your tumor.

What the Evidence Shows

According to discussions from leading oncologists, treatment decisions should be based on:

• Your tumor's complete molecular profile (not just HER2 status)
• Stage of disease
• Your overall health and ability to tolerate treatment
• Whether you're a candidate for clinical trials with newer approaches

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Your oncologist will determine the most appropriate sequencing and specific drugs for YOUR case based on your complete clinical picture, pathology results, and individual factors.